Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Systemic Lupus Erythematosus
NCT00071487Phase 2Completed
- Sponsor
- Human Genome Sciences
- Start
- Oct 2003
- Primary completion
- Aug 2005
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of belimumab in systemic lupus erythematosus (SLE), sponsored by Human Genome Sciences. Primary endpoints: Percentage Change From Baseline in SELENA SLEDAI Score at Week 24 and Time to First Mild/Moderate or Severe SLE Flare (SLE Flare Index) at 52 weeks. Started Oct 2003; status: completed.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00071487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071487.